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SUMMARY  
Carcinomas of the thyroid with Ewing family tumour element (CEFTEs) are small cell thyroid 
tumours with epithelial differentiation that co-exist with papillary thyroid carcinoma (PTC) 
foci, disclose p63 expression, EWSR1-FLI1 rearrangement and likely a favorable prognosis. 
Two histogenetic hypotheses have been advanced regarding the origin of CEFTEs: arising 
in PTCs or in solid cell nests (SCN). 
A total of 3 CEFTEs, 54 PTCs and 10 SCNs were collected from March 2011 to February 
2015 and the morphological features of each case were reviewed by two pathologists. 
Fluorescence in situ hybridization (FISH) technique was performed in sections of all cases 
obtained from paraffin embedded tissue to search for the presence of EWSR1 
rearrangements.  
All 3 CEFTEs disclosed the EWSR1-FLI1 rearrangement both in the small cell and in the 
PTC components. Out of the 54 PTC cases, 28 (51.9%) were positive, 20 (37.0%) were 
negative and 6 (11.1%) were inconclusive for EWSR1 rearrangement; in 2 of the positive 
PTC cases the EWSR1-FLI1 rearrangement was detected. Classic PTC disclosed more 
often the EWSR1 rearrangement than other PTC variants (p=0.031). PTCs with EWSR1 
rearrangement disclosed less often nuclei with EWSR1 polysomy than those without 
EWSR1 rearrangement (p=0.001). Out of the 10 SCNs, 7 (70.0%) were negative and 3 
(30.0%) were inconclusive for the EWSR1 rearrangement. Monosomic nuclei were more 
frequent (mean of 44.3%) in SCNs than in PTCs (p<0.001). 
The presence of the EWSR1-FLI1 rearrangement in PTC component of all studied CEFTEs 
and the existence of the EWSR1 rearrangement in some PTCs favours the origin of CEFTE 
from PTC. The high frequency of EWSR1 rearrangements in PTC may represent a new 
diagnostic marker of these tumours.   
 
Keywords: Papillary thyroid carcinoma, EWSR1 rearrangement, Small cell carcinoma, 
EWSR1-FLI1, Ewing sarcoma.  
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RESUMO 
Carcinomas da tiroide com elementos de tumores da família Ewing (CEFTEs) são tumores 
da tiroide de pequenas células com diferenciação epitelial que coexistem com focos de 
carcinoma papilar da tiroide (PTC), expressam p63, rearranjo EWSR1-FLI1 e 
provavelmente um prognóstico favorável. Duas hipóteses histogenéticas para a origem dos 
CEFTEs têm sido avançadas: origem em PTCs ou em solid cell nests (SCN). 
Um total de 3 CEFTEs, 54 PTCs e 10 SCNs foram selecionados desde março de 2011 até 
fevereiro de 2015 e as características morfológicas de cada caso foram revistas por dois 
patologistas. A técnica de hibridização in situ por fluorescência (FISH) para detetar a 
presença de rearranjos do EWSR1 foi executada em lâminas com cortes colados de todos 
os casos obtidos a partir de blocos com tecidos impregnados em parafina. 
Todos os casos de CEFTE revelaram rearranjo EWSR1-FLI1 tanto no componente de 
pequenas células como no componente PTC. Dos 54 casos de PTC, 28 (51,9%) foram 
positivos, 20 (37,0%) foram negativos e 6 (11,1%) foram inconclusivos para o rearranjo 
EWSR1; em 2 casos PTC positivos foi detetado o rearranjo EWSR1-FLI1. Os casos de 
PTC clássico revelaram com maior frequência o rearranjo do EWSR1 do que outras 
variantes de PTC (p=0.031). PTCs com rearranjo EWSR1 revelaram menor frequência de 
núcleos com polissomia do EWSR1 do que aqueles sem rearranjo do EWSR1 (p=0.001). 
Dos 10 casos de SCN, 7 (70,0%) foram negativos e 3 (30,0%) inconclusivos para o 
rearranjo do EWSR1. Núcleos monossómicos foram mais frequentes (média de 44,3%) 
nos SCNs do que nos PTCs (p<0.001). 
A presença do rearranjo EWSR1-FLI1 na componente PTC de todos os CEFTEs estudados 
e a existência de rearranjo do EWSR1 em alguns PTCs favorece a origem do CEFTE no 
PTC. A elevada frequência de rearranjos do EWSR1 em PTC pode representar um novo 
marcador de diagnóstico para estes tumores.  
 
Palavras-chave: Carcinoma papilar da tiroide, Rearranjo EWSR1, Carcinoma de células 
pequenas, EWSR1-FLI1, Sarcoma de Ewing. 
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1.1 - THYROID GENERAL ASPECTS 
The thyroid gland consists of two bulky lobes connected by a relatively thin isthmus, usually 
located below and anterior to the larynx (Figure 1). This organ develops embryologically 
from an evagination of the developing pharyngeal epithelium that descends from the 
foramen cecum at the base of the tongue to 
its normal position in the anterior neck (1).  
The thyroid is an endocrine organ that is 
responsible for the production and controlled 
release of thyroid hormones that are 
essential to fetal development and regulation 
of many metabolic processes (2). The thyroid 
parenchyma is constituted by lobules, each 
composed by 20 to 40 dispersed follicles, 
filled with thyroglobulin (TG), the iodinated 
precursor protein of active thyroid hormone.  
The regulation of the thyroid metabolism is 
complex and involves the central nervous 
system. Briefly, the hypothalamus produce thyroid releasing hormone (TRH) that stimulates 
the pituitary gland for producing thyroid stimulating hormone (TSH). TSH binds to the 
receptor on the thyroid follicular epithelium cells which active these cells to convert TG into 
thyroxine (T4) and lesser amounts of 
triiodothyronine (T3) (Figure 2). T4 and T3 are 
released into the systemic circulation, where 
most of these peptides are reversibly bound 
to circulating plasma proteins (1).  
The lateral lobes of the thyroid also harbor 
the C-cells which are neuroendocrine cells 
responsible for the production of calcitonin. 
Both C-cells and squamoid main cells may 
constitute cellular aggregates, the so called 
solid cell nests (SCN) (2, 3).  
The thyroid provides an attractive model to 
study the steps that are involved in the 
neoplastic process.  
 
Figure 1 - Localization of thyroid gland. (www.med-
health.net) 
Figure 2 - Metabolism of thyroid gland. (www.my 
housecallmd.com)  
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1.2 - PRIMARY SMALL CELL TUMOURS OF THE THYROID 
Thyroid tumours can assume variable histological appearances, including the small cell 
phenotype that may occur in lymphoma, poorly differentiated carcinoma, medullary 
carcinoma, secondary neoplasms, primary extraeskeletal Ewing family tumours (PEEFTs) 
and other tumours with uncertain histogenesis (4-7).  
The small cell tumours of the thyroid are rare and, for years, have been considered a major 
issue of debate (4). The differential diagnosis of small cell thyroid tumours is classically 
based upon the immunohistochemical profiles of these tumours (5) (Table 1). 
Table 1 - Differential diagnosis of thyroid tumours with neuroendocrine differentiation.   
 Expression of Neuroendocrine Markers 
Size of tumour cells 
Calcitonin + 
CGRP + 
Chromogranin + 
Calcitonin –  
CGRP + 
Chromogranin +  
Calcitonin – 
CGRP – 
Chromogranin + 
Large / intermediate cells 
MTC 
Metastases of NET 
C-cell derived calcitonin-
free atypical MTC 
Primary NET 
Small cells 
MTC 
Metastases of NET 
Not described 
Metastases of NET 
Paraganglioma 
Parathyroid tumour 
Primary NET 
Metastases of NET 
PEEFT/CEFTE (with 
neuroendocrine 
differentiation) 
Legend: +, Positive; –, Negative; CGRP, Calcitonin gene related peptide; MTC, Medullary thyroid carcinoma; 
NET, Neuroendocrine tumour. (Eloy C. et al. 2014) 
1.2.1 - PRIMARY EXTRAESKELETAL EWING FAMILY TUMOUR (PEEFT) 
PEEFTs are rare bone or soft tissue sarcomas (8-10), commonly arising in the paravertebral 
region, chest wall, retroperitoneum, and lower extremities (11, 12). These neoplasms may 
also arise in other organs and sites, such as lung, skin, intestine, kidney and thyroid. 
PEEFTs are rare in the region of head and neck (13) and are usually diagnosed in childhood 
and young adults (9, 12, 14). In these cases the differential diagnosis from other sarcomas, 
carcinomas or lymphomas can be difficult (15). Histologically, PEEFT are characterized by 
a small round blue cell population (12, 13, 16) disclosing neuroectodermal differentiation at 
a variable extent (10, 12) (Figure 3).  
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PEEFT immunohistochemical profile 
includes a membrane diffuse expression 
for CD99 (Cluster of differentiation 99) 
(10, 14), however CD99 expression is not 
specific to PEEFT, as it has also been 
detected in other neoplasms (12). PEEFT 
has also expression for vimentin, 
synaptophysin and neuron specific 
enolase (NSE) and has absence of 
expression of cytokeratins and E-
cadherin (5).   
PEEFTs are characterized by a typical chromosomal rearrangement involving the EWSR1 
gene (14, 17-19), that is thought to be the initiating event in the development of this 
neoplasm (14). The fusion products that result from EWSR1 and partners rearrangement, 
commonly results from fusion of the N-terminal transcription-activating domain of EWSR1 
and the C-terminal DNA-binding domain of the fusion partner (9). One of the most common 
fusion partners of EWSR1 is the FLI1 gene (9, 20-22) (Figure 4). The EWSR1-FLI1 
rearrangement involving, respectively, the chromosome 22 and the chromosome 11, has 
been documented in 85% of the cases of soft tissues PEEFTs (8, 10, 16, 17) and in all of 
the cases of thyroid PEEFTs (5, 15, 22). EWSR1-FLI1 codifies an oncoprotein and is 
recognized as a DNA-binding transcriptional regulator (21). Nearly 12 different in-frame 
EWSR1-FLI1 chimeric transcripts have been observed containing different combinations of 
exons from EWSR1 and FLI1, resulting in various combinations of EWSR1 and FLI1 
genomic breakpoints (10, 12). These tumor-specific molecular rearrangements can be 
visualized by a “gold standard” method for fusion gene detection, fluorescence in situ 
hybridization (FISH) (9). 
Figure 3 - Histological aspect of PEEFT (H&E - 200x). 
(Biswas G. et al. 2006) 
Figure 4 - Diagrammatic representation of the EWSR1-FLI1 rearrangement (www.vai.org) 
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EWSR1-FLI1 rearrangement is useful for primary diagnosis of PEEFT, may provide 
prognostic information, and is considered an optimal drug marker for specific therapy (8, 
19, 20).  
 
1.2.2 - CARCINOMA OF THE THYROID WITH EWING FAMILY TUMOUR ELEMENTS (CEFTE) 
The recent identification of a small 
cell carcinoma of the thyroid with 
Ewing family tumour elements 
(CEFTE) brought an extra difficulty 
to the small cell thyroid tumours 
differential diagnosis (4, 6). CEFTE 
are small cell thyroid tumours with 
epithelial differentiation that 
typically co-exist with papillary 
thyroid carcinoma (PTC) foci, and 
display vascular invasion (Figure 
5), p63 and CD99 expression, 
negativity for TTF-1 and TG, Ewing sarcoma EWSR1-FLI1 rearrangement and a favorable 
prognosis, despite their poorly differentiated appearance, high mitotic index and foci of 
necrosis (5-7). These CEFTE must be distinguished from the rare true PEEFTs arising in 
thyroid (15). Two hypotheses for the origin of CEFTE have been advanced:  
 The topographic co-existence of a small cell tumour and PTC foci in CEFTE raised 
the hypothesis of a putative histogenic relation between these tumours, where PTC 
cells acquired the EWSR1-FLI1 rearrangement and lost the thyroid differentiation 
(negative for TTF-1 and TG) (5, 7).  
 The expression of p63 in the small cell component of CEFTE and the previous 
association between PTC and SCN that typically express p63, raised the possibility 
of an alternative histogenic hypothesis to CEFTE based upon an origin on SCNs (5, 
7). 
 
1.3 - PAPILLARY THYROID CARCINOMA (PTC) 
Most cases of thyroid carcinoma occur in adults, although papillary thyroid carcinomas 
(PTC) (75% to 85% of cases) may also occur in childhood (23-26). PTC is the most frequent 
malignant thyroid neoplasm (27-30) and the most frequent type of endocrine cancer (24, 
Figure 5 - Histological aspect of CEFTE (H&E - 100x)  
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29, 31, 32). PTC is sporadic in about 95% of the cases and familial in the remaining 5% 
(29). The etiology of PTC is related to environmental, genetic and hormonal factors (33). 
Some of PTCs are associated with previous exposure to ionizing radiation (1, 24, 26). The 
usual presentation of PTC is a thyroid nodule or a neck mass (25) that can be present as 
solitary or multifocal lesions within the thyroid (34-36). According to recent epidemiological 
surveys the incidence rates of PTC (4 and 12 per 100.000 in men and women, respectively) 
are increasing (24). PTCs are indolent lesions with 10-year survival rates of 80% to 95% 
(25, 28, 30, 34).  
PTC may co-exist with other thyroid tumours with small cell phenotype, namely poorly 
differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) (5, 6, 31, 
37, 38). PDTCs represent 4-7% of thyroid neoplasms (39). Morphologically, PDTCs are 
found in an intermediate position between differentiated and ATC, with differentiation loss 
and invasive growth, regional node and distant metastases (39, 40). PDTCs often occur in 
the female patients in sixth decade of live (39). ATCs represent less than 1% of all thyroid 
neoplasms and are among the most aggressive and lethal human neoplasms, with frequent 
distant metastases and poor prognosis (40). The mortality rate is higher than 90% in the 
first year, with a mean survival of 6 months after diagnosis (1, 37). Individuals with ATC are 
older than those with other types of thyroid cancer, with a mean age of 65 years at diagnosis 
(1, 38, 40).  
It is usually accepted that PDTC and ATC occur either de novo or progress from a pre-
existing well differentiated carcinoma (usually PTC) through a multistep process of genetic 
and epigenetic changes, typical of PTCs (for example BRAF mutation), that lead to clonal 
expansion and neoplastic development (25, 40).  
PTCs, particularly microcarcinomas (found incidentally and measuring ≤10mm in diameter 
(33, 41) and PTCs with a conventional growth pattern, exhibit BRAF point mutations in up 
to 83% of cases, almost always in the same hot spot than melanoma (V600E) (24, 32, 38, 
42-44). BRAF mutations have been associated to advanced age at time of diagnosis, male 
gender, absence of total encapsulation, extra-thyroid extension, lymph node metastases, 
distant metastases, recurrence and higher tumour stages (32). This mutation consists in a 
transversion from thymine to adenine in position 1799, leading to the substitution of a valine 
by a glutamate in codon 600 (24, 42, 45). 
Other well known rearrangements have been documented in PTC, such as those involving 
the tyrosine kinase receptor gene RET (located on chromosome 10q11) (45-47), also 
known as RET-PTC rearrangement, is the most common rearrangement identified to date 
in thyroid papillary carcinomas (29, 41, 46, 48), and the NTRK1 gene (neurotrophic tyrosine 
kinase receptor 1, located on chromosome 1q) (24), in 35% and 15% of cases, respectively 
(28, 42, 45, 48). RET and NTRK1, encode membrane tyrosine kinase (TK) receptors for 
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neural growth factors (49). Some studies have shown that the tumourigenic properties of 
RET-PTC and NTRK1 result from the aberrant and persistent activation of their TK domain 
(24). 
RET-PTC is more frequent in PTCs that have a classic architecture, microcarcinomas (31), 
PTCs associated with radiation exposure, tumours in children and young adults (24, 48), 
but are rarely found in familial cases (29). RET-PTC was the first rearrangement proposed 
as a marker for PTC, however, the initial enthusiasm was tempered by finding of this 
rearrangement in benign lesions like Hashimoto’s thyroiditis (HT) and follicular adenomas 
and carcinomas of oncocytic type (50).  
NTRK1 rearrangements are associated with radiation exposure and spontaneous thyroid 
tumours (49). The breakpoints of NTRK1 rearrangements have been described in the 
perimembrane region upstream of TK domain of the receptor protein (33). These molecular 
alterations are an opportunity for develop news target therapies. 
Despite all these molecular data, 
PTC diagnosis still depends on the 
identification of typical nuclei with 
large, irregular, clear, grooved 
aspect, occasionally displaying 
pseudo-inclusions, psammoma 
bodies and squamous metaplasia 
(24, 33, 36, 42) (Figure 6). PTCs 
can be diagnosed pre-operatively 
by fine needle aspiration biopsy 
(FNAB) and cytological evaluation. 
FNAB is helpful for distinguishing 
benign from malignant nodules and 
has an accuracy of 95% and false-negative rate of 4% to 6% (30).  
PTCs may be solid or cystic, may have an infiltrative or expansive growth pattern, and may 
show direct extension beyond the thyroid to adjacent tissues (33). Lesional calcification is 
a common feature (26). Metastases occur frequently to adjacent cervical lymph nodes, 
which can be the initial manifestation of the disease (25, 26, 35), nevertheless, PTCs 
generally harbor a good prognosis (1, 26, 46). Despite the good prognosis, PTCs may give 
rise to recurrences and/or distant metastases, sometimes many years after diagnosis (32). 
Distant metastases of PTC to lungs and bones occur in 5-7% of cases (26, 45). In general, 
the prognosis is less favorable among elderly persons, large tumour size, male gender, 
multicentricity and in patients with invasion of extra-thyroidal tissues and/or distant 
metastases (1, 26, 32).  
Figure 6 - Histological aspect of classic PTC (H&E - 200x) 
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The first-line treatment of PTC is surgical excision (total or partial thyroidectomy), adjuvant 
radioiodine (131I) ablation and TSH suppressive therapy (23, 30, 45). Usually the patients 
respond very well to these treatments but sometimes are resistant to radioactive iodine 
(RAI) (24, 45), and 20% of all PTC patients ultimately show disease progression (23). 
Recent study demonstrated that patients with progressive thyroid cancer, refractory to RAI, 
have responded to “targeted” multikinase inhibitors (for example selumetinib in combination 
with other agents), which inhibit angiogenesis and not the tumour cell, in PTCs that harbor 
the BRAF mutation (51). Sorafenib, also has been approved for differentiated thyroid cancer 
refractory to RAI with relevant secondary effects, justifying the need to explore new 
treatment approaches (45). 
 
1.4 - SOLID CELL NESTS (SCN) 
Solid cell nests of thyroid represent remnants of ultimobranchial body (52, 53) and are a 
normal component of the human thyroid gland (44, 53), found incidentally in about 60% of 
adult thyroids and in 89% of neonatal thyroids, if the entire glands were examined (44). SNC 
are irregular structures of about 1 mm in maximal diameter, which usually is located mainly 
in the middle or occasionally in the upper third of the thyroid lateral lobes, between the 
thyroid follicles (18). SCN display single or multiple clusters of 2 cell types referred to as 
main cells and C-cells (44, 52, 53). SCN may be difficult to distinguish from squamous 
metaplasia, primary or metastatic squamous cell carcinoma, papillary and medullary 
microcarcinoma and C-cell hyperplasia (52, 53). 
The nuclei of SCN, centrally 
located, are round to oval and 
fusiform in shape with an 
eosinophilic cytoplasm (18, 44, 53) 
(Figure 7). SCN are predominently 
composed by non-keratinizing 
squamoid cells in solid nests or 
cystic formation filled with PAS-
positive granular material after 
diastase digestion and acid mucins 
(18, 52, 53). This squamoid main 
cells are immunochemically 
positive for p63, galectin-3, carcinoembryonic antigen (CEA) and cytokeratins (CAM5.2, 
AE1/AE3, 34βE12, CK7 and CK19) (44, 52). Main cells of SCN display a basal/stem cell 
phenotype (p63 and basal cytokeratin positivity) (52, 53).  
Figure 7 - Histological aspect of SCN (H&E - 200x) 
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2 - AIM OF THE STUDY  
In an attempt to understand the histogenesis of CEFTE, we searched for the EWSR1-FLI1 
rearrangements in the PTC component of CEFTEs, and studied the frequency of this 
rearrangement in a series of PTCs and in a series of SCNs. 
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3 - MATERIALS AND METHODS  
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3.1 - BIOLOGICAL SAMPLES 
Thyroid lesions were retrieved from the Pathology Archive of Ipatimup Diagnostics at 
Ipatimup. A total of 3 CEFTEs (received in consultation), 54 consecutive PTCs non 
associated to small cell tumours and 10 SCNs topographically non associated to other 
lesions were collected from March 2011 to February 2015. The clinical data was collected 
from the patient files and the morphological features of each case were reviewed by two 
pathologist (CE and AP). For each case, all available haematoxylin and eosin stained 
sections were observed and one area (in PTCs and SCNs) or two (in CEFTE, 
comprehending the small cell component and the PTC component) were selected for 
fluorescence in situ hybridization analysis, in a single slide per case. 
 
3.2 - FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 
Fluorescence in situ hybridization (FISH) is the “gold standard” method used for fusion gene 
detection (23). FISH is a powerful technique for quantitative analysis of chromosomes and 
genes and can be applied in various samples, does not require cell culture or metaphase 
nuclei (54). FISH technique was performed in 4µm tissue sections obtained from paraffin 
embedded tissue of the 3 CEFTEs, 54 cases of PTCs and 10 SCNs. Tissue sections were 
extended on polysine adhesion slides (Thermo Scientific, Waltham, MA USA), following the 
next procedure: 
 Desparaffinization with xylene and a decreasing alcohol series, until water type I. 
 Antigen retrieval was performed with citrate buffer pH6.0 at 95ºC (Thermo Scientific, 
Waltham, MA USA).  
 It consists in breaking the methylenic bridges induced by formalin, allowing 
access to the present DNA in the nucleus and consecutive connection of the 
probe to the interest gene. 
 Enzyme digestion with 0.5% pepsin at 37ºC (Sigma-Aldrich Quimica, Sintra, 
Portugal).  
 Pepsin is always prepared extemporaneously and to make active pepsin is 
used 1M hydrochloric acid (HCl), since it only reacts in acidic.  
 This step helps to recover the effects of covalent cross-links which were 
formed by the fixation in formalin.  
 A controlled enzyme digestion can improve the penetration of the probe into 
the interest gene. 
 Codenatured at 79ºC and hybridization at 37ºC were performed overnight with a 
ZytoLight SPEC EWSR1-FLI1 TrickCheck Probe (ZytoVision, Bremerhaven, 
Germany) in a SPOT-Light CISH Hybridizer.  
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 Wash in 2xSSC at 72ºC, for removing the excess of probe that did not react with the 
interest gene. 
 The stringency of 2xSSC solution is important to the quality of washing, 
which may be altered by the concentration of salts, temperature and the time 
in the solution.  
 Nuclei were counterstained with DAPI/Dura-Tect mounting solution (ZytoVision, 
Bremerhaven, Germany).  
 Due to DAPI high selectivity for DNA as well as high permeability, this 
counterstain allows a good contrast nuclear, and a cytoplasm with a small 
background. 
Appropriated positive and negative controls were used in each set of slides. Fluorescence 
hybridization signals were analyzed and recorded with a Zeiss Z.01 fluorescence 
microscope (Carl Zeiss, Germany). In each case, 50 nuclei were scored for the presence 
of EWSR1 rearrangement, EWSR1 monosomy, EWSR1 polysomy and EWSR1-FLI1 
fusion. EWSR1 rearrangement was considered if a signal separation of the 5’-orange and 
the 3’-green of the EWSR1 probe was present. If this signal separation was observed 
together with the fusion of the 5’-orange signal of EWSR1 and the blue signal of FLI1, the 
case was considered positive for EWSR1-FLI1 fusion. 
For establishing the cut-off level above which a case should be considered positive for 
EWSR1 rearrangement, a FISH analysis was performed on 10 normal thyroid samples 
obtained from the Pathology Archive of Ipatimup Diagnostics at Ipatimup. The average 
percentage of EWSR1 rearrangements in normal nuclei was 0.8%. Following De Vries et 
al., a value of three times the average percentage was used for calculation of the cut-off 
value (55). In the presence of ≥2.4% nuclei with break-apart sign of the region of the EWSR1 
gene, the case was considered positive for EWSR1 rearrangement. Cases with nuclei 
without signals in less than 50 nuclei were classified as inconclusive. A normal nucleus for 
this chromosomal region was accepted when exhibiting 2 signals fusion of EWSR1 (5’-
orange and 3’-green) and 2 blue signals of FLI1 separated. Monosomy was considered 
when the number of signals in each nucleus was inferior to those observed the normal 
nuclei, and polysomy was considered when the number of signals in each nucleus was 
superior to those observed the normal nuclei.  
FISH is a laborious and time-consuming technique that requires the observation of a large 
number of nuclei by an experienced operator. However, this method provides important 
information on the percentage of cells harboring the EWSR1 rearrangement. 
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3.3 - STATISTIC ANALYSIS 
Statistical analyses were performed using the Statistical Package for the Social Sciences 
(SPSS) version 20 for Windows. The Pearson´s chi-square (χ2) test (or Fisher exact 
probability test if appropriate) was used for comparison of qualitative variables and the t-
test, Mann-Whitney test  and Pearson´s correlation were used for quantitative variables. 
The level of significance was set at p<0.05. 
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4.1 - CARCINOMA OF THE THYROID WITH EWING FAMILY TUMOUR ELEMENTS (CEFTE)  
Three cases of CEFTE were included in the study, from 2 males and 1 female, with mean 
age of 32 years-old (24-42 years) and a mean tumour size of 33mm. All of the CEFTE cases 
disclosed expansive growth, vascular invasion and co-existence of the small cell component 
with a PTC component.  
 
Figure 8 - CEFTE case disclosing a follicle of PTC component surrounded by small cells (A: H&E; 400x). The 
PTC component discloses TTF-1 expression at variance with the small cells (B: TTF-1; 400x) but does not 
express p63, that is expressed in the small cells (C: p63; 400x). The FISH analysis of this area demonstrates 
the presence of EWSR1 break apart signals with fusion signals with FLI1 in both the cells of the PTC and the 
small cells – one normal signal of EWSR1 (5’-orange and 3’-green) and one fusion signal with FLI1 (5’-orange 
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signal of EWSR1 fused with one blue signal of FLI1) (D,E,F: 600x). In G there is a normal nucleus of the normal 
appearing thyroid tissue for comparison purposes where it is possible to identify two signals of EWSR1 (5’-
orange and 3’-green) and two blue signals of FLI1 separated (600x). 
The small cell component of CEFTE was positive for p63 and CD99, as reported before (7). 
The PTC foci were positive for TTF-1 and negative for p63. The follow-up period for each 
case is 3, 4 and 15 years, and the patients are alive and well without signs of the disease. 
All of the three studied CEFTEs were positive for the EWSR1-FLI1 rearrangement, both in 
small cell and PTC components (Figure 8). 
4.2 - PAPILLARY THYROID CARCINOMA (PTC)  
Table 2 summarizes the features of the 54 PTCs cases, including 43 females (79.6%) and 
11 males (20.4%) with mean age of 49 years-old at the diagnosis (11-78 years) and mean 
tumour size of 17mm (5-53mm). This series included 11 classic PTCs (20.4%), 18 follicular 
variants of PTCs (33.3%), 19 papillary microcarcinomas (35.2%) and 6 trabecular/solid 
variants of PTCs (11.1%). PTCs disclosed infiltrative growth pattern in 22 cases (40.7%) 
and expansive growth patterns in 32 cases (59.3%). 24 cases (44.4%) were multicentric 
and 30 cases (55.6%) were unifocal. It was observed vascular invasion in 19 cases (35.2%) 
and in 35 cases (64.8%) not. 10 cases (18.5%) had extra-thyroid extension while 44 cases 
(81.5%) were limited to the thyroid parenchyma. Only 7 cases (13.0%) developed lymph 
nodes metastases and none of them had distant metastasis. The other thyroid was normal 
in 33 cases (61.1%), had Hashimoto’s thyroiditis in 12 cases (22.2%), thyroiditis in 4 cases 
(7.4%) and goiter in 5 cases (9.3%). The tumour was in the right lobe in 28 cases (51.9%), 
in the left lobe in 23 cases (42.5%) and in the isthmus in 3 cases (5.6%). Capsule was 
present in 28 cases (51.9%) and absence in 26 cases (48.1%). The majority of the cases 
were in stage I (42 cases; 77.8%).  
Table 2 - Clinico-pathological features of the 54 PTC cases 
Case 
ID 
Gender 
Age 
(year) 
Size 
(mm) 
Variant GP Mult VI ExE LNM OT Loc Cap St 
A1 F 32 9 Micro Inf – – + – Nm RL – I 
A2 F 78 15 Classic Exp + – – – HT Is – I 
A3 F 52 8 Micro Inf – – – – Nm LL – I 
A4 F 37 22 Follicular Exp – – – – G RL + I 
A5 F 11 16 Trab/Solid Inf + – – – HT LL – I 
A6 F 76 10 Follicular Exp – – – – G LL – I 
A7 M 39 29 Classic Exp + + + + Nm RL + I 
A8 F 38 15 Classic Inf – – – – Nm RL – I 
A9 F 45 15 Classic Exp + – – – Nm LL + I 
A10 F 29 9 Micro Inf + + + + HT RL – I 
A11 F 46 17 Follicular Exp – + – – Nm RL + I 
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A12 F 62 8 Micro Inf + – – – HT LL – I 
A13 F 73 10 Micro Exp – + – – Nm LL + I 
A14 F 78 8 Micro Exp + + + – Nm LL + III 
A15 F 46 18 Follicular Exp – – – – HT LL + I 
A16 M 44 12 Classic Exp + + – + Nm LL + I 
A17 M 56 45 Follicular Exp – – – – Nm LL + III 
A18 M 63 20 Follicular Exp + – – – T Is + I 
A19 F 52 35 Follicular Exp + – – – HT RL + II 
A20 F 27 10 Micro Inf – + – + Nm RL – I 
A21 F 42 26 Classic Inf + + + + HT Is – I 
A22 F 54 35 Follicular Exp – – – – Nm RL + II 
A23 F 58 7 Micro Inf + + + – Nm LL – III 
A24 F 60 14 Trab/Solid Exp – – – – Nm LL + I 
A25 F 20 23 Follicular Exp – + – – Nm LL + I 
A26 F 36 20 Follicular Exp + – – – HT LL + I 
A27 F 45 14 Follicular Exp – – – – Nm RL – I 
A28 M 35 6 Micro Exp + – – – Nm LL + I 
A29 F 39 17 Classic Inf + + – + Nm RL – I 
A30 F 18 28 Follicular Exp – – – – Nm RL + I 
A31 F 54 14 Classic Exp + – – – Nm RL + I 
A32 M 34 50 Follicular Exp + – – – G RL + I 
A33 M 35 53 Follicular Exp + – – – Nm LL + I 
A34 M 55 11 Classic Inf – – – – G RL – I 
A35 F 20 13 Trab/Solid Exp – – – – T RL – I 
A36 F 54 6 Micro Exp – – – – HT LL + I 
A37 F 57 6 Micro Inf – – – – G RL – I 
A38 F 39 8 Micro Inf – – – – Nm RL – I 
A39 F 48 6 Micro Exp + – – – HT RL – I 
A40 F 48 7 Micro Inf – + + – Nm RL – III 
A41 F 47 15 Trab/Solid Exp – + – – Nm LL + I 
A42 M 47 17 Classic Inf + + – – Nm RL – I 
A43 F 40 5 Micro Inf – – – – T LL – I 
A44 F 78 9 Micro Inf + – – – Nm LL – I 
A45 F 57 18 Follicular Exp – + – – HT RL + I 
A46 F 66 34 Follicular Exp + – – – Nm RL + II 
A47 F 40 6 Micro Inf – – + – Nm RL – I 
A48 M 68 46 Follicular Exp – + – – Nm RL + III 
A49 F 49 15 Classic Inf + + – + HT RL – III 
A50 F 53 14 Follicular Exp – – – – Nm RL + I 
A51 F 71 21 Trab/Solid Exp – – – – Nm RL + II 
A52 M 63 22 Trab/Solid Inf + + + – Nm LL – III 
A53 F 54 10 Micro Inf – – – – T LL – I 
A54 F 54 9 Micro Inf – + + – Nm LL – III 
Legend: M, male; F, female; Micro, Microcarcinoma; Trab/Solid, Trabecular/Solid; GP, Growth pattern; Inf, 
Infiltrative; Exp, Expansive; Mult, Multicentricity; VI, Vascular invasion; ExE, Extra-thyroid extension; LNM, 
Lymph node metastases; EWSR1 rearr, EWSR1 rearrangement; +, Present; –, Absent; OT, Other Thyroid; Nm, 
Normal; HT, Hashimoto’s thyroiditis; G, Goiter; T, Thyroiditis; Loc, Localization of tumour; RL, Right lobe; LL; 
Left lobe; Is, Isthmus; Cap, Capsule; St, Stage. 
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Considering the occurrence of EWSR1 rearrangement, a total of 28 cases (51.9%) were 
positive, 20 cases (37.0%) were negative and 6 cases (11.1%) were inconclusive. Two 
cases (A21 and A32) disclosed the EWSR1-FLI1 fusion signal (7.1% in 28 positive cases, 
3.7% in a total of 54 cases) (Figure 9). The percentage of polysomic nuclei in PTC case 
ranged from 0 to 40% (mean value=13.3%). The percentage of monosomic nuclei in PTC 
case ranged from 2 to 44% (mean value=17.2%) (Table 3).  
 
Figure 9 - The FISH analysis demonstrates the presence of EWSR1 break apart signals without fusion signals 
with FLI1 – one signal fusion EWSR1 (5’orange and 3’green), two separated 3’green and 5’orange signals of 
EWSR1 and two separated blue signals of FLI1 (A:600x), and demonstrates the presence of EWSR1 break 
apart signal with fusion signal with FLI1 – one normal signal of EWSR1 (5’-orange and 3’-green) and one fusion 
signal with FLI1 (5’-orange signal of EWSR1 fused with one blue signal of FLI1) (B:600x). 
Table 3 - FISH analysis of the 54 PTC cases 
Case ID EWSR1 rearrangement EWSR1 polysomy (% cells) EWSR1 monosomy  (% cells) 
A1 I I I 
A2 P 4 6 
A3 I I I 
A4 P 20 8 
A5 I I I 
A6 N 14 18 
A7 P 4 28 
A8 N 40 10 
A9 P 16 8 
A10 N 20 12 
A11 P 0 36 
A12 N 14 32 
A13 N 24 18 
A14 N 36 10 
A15 P 2 44 
A16 P 10 8 
A17 N 24 4 
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A18 N 20 18 
A19 P 18 10 
A20 N 18 16 
A21 P 12 6 
A22 N 8 42 
A23 N 22 6 
A24 P 14 16 
A25 N 16 32 
A26 N 8 18 
A27 N 34 8 
A28 P 6 20 
A29 P 12 14 
A30 N 2 42 
A31 I I I 
A32 P 4 8 
A33 P 0 26 
A34 P 4 18 
A35 I I I 
A36 P 6 8 
A37 N 14 34 
A38 P 2 16 
A39 P 14 12 
A40 N 28 8 
A41 P 0 34 
A42 P 12 22 
A43 P 12 8 
A44 P 12 14 
A45 P 12 10 
A46 P 10 16 
A47 P 14 12 
A48 N 4 22 
A49 P 10 2 
A50 N 6 40 
A51 N 34 6 
A52 I I I 
A53 P 6 12 
A54 P 18 8 
Legend: P, Positive; N, Negative; I, Inconclusive. 
Classic PTC disclosed more often the EWSR1 rearrangement than the other PTC variants 
(90.0% in classic PTCs and 50.0% in other variants; p=0.031). The PTC cases with EWSR1 
rearrangement had lower percentage of nuclei with polysomy than PTC cases without 
EWSR1 rearrangement (mean of 9.1% vs 19.3%, respectively; p=0.001). There was no 
statistically difference of the percentage of nuclei with monosomy between the PTC cases 
with or without EWSR1 rearrangement (mean of 15.4% vs 19.8%, respectively; p=0.185).  
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There was no statistically significant association between PTC clinico-pathological features 
and the FISH results (Table 4). 
Table 4 - Statistic analysis of clinico-pathological features and results of the FISH analysis in PTCs  
 
EWSR1 with 
rearrangement 
EWSR1 without 
rearrangement 
p 
Gender 
(Female / Male) 
21 / 7 17 / 3 0.488 a 
Age 
(Mean ± Standard Deviation) 
48.6 ± 11.6 51.5 ± 18.4 0.535 b 
Size 
(Mean ± Standard Deviation) 
17.8 ± 12.5 17.8 ± 12.2 0.997 b 
Variant 
(Classic / Other) 
9 / 19 1 / 19 0.031 a 
Growth pattern 
(Infiltrative / Expansive) 
11 / 17 7 / 13 0.762 c 
Multicentricity 
(Present / Absent) 
15 / 13 6 / 14 0.105 c 
Vascular invasion 
(Present / Absent) 
10 / 18 8 / 12 0.762 c 
Extra-thyroid extension 
(Present / Absent) 
4 / 24 4 / 16 0.703 a 
Lymph node metastases 
(Present / Absent) 
5 / 23 2 / 18 0.683 a 
Other thyroid 
(Normal / Other) 
15 / 13 14 / 6 0.251 c 
Localization of tumour 
(LD / LE) 
14 / 12 11 / 8  0.787 c 
Capsule 
(Present / Absent) 
15 / 13 11 / 9 0.922 c 
Capsule invasion 
(Present / Absent) 
11 / 4 5 / 6 0.228 a 
Stage 
(I / Other) 
24 / 4 13 / 7 0.162 a 
EWSR1 polysomy 
(Mean ± Standard Deviation) 
9.1 ± 5.9 19.3 ± 11.1 0.001 b 
EWSR1 monosomy 
(Mean ± Standard Deviation) 
15.4 ± 10.1 19.8 ± 12.8 0.185 b 
  Legend: a, Fisher exact probability test; b, t-test; c, Pearson’s chi-square (x2)   
 
 
29 
 
4.3 - SOLID CELL NESTS (SCN)  
Table 5 summarizes the clinico-pathological 
features and the result of the FISH analysis in 
the SCNs series. Ten SCNs were detected in 
thyroids from 7 females and 3 males, with a 
mean age of 54 years-old (32-74 years). 
Seven SCNs were negative for EWSR1 
rearrangement (70.0%) and 3 cases were 
inconclusive (30.0%). All studied SCNs with 
conclusive results disclosed EWSR1 
monosomy in at least 30% of the tumour cells 
(mean of 44.3%) while only 18.8% of PTCs 
disclosed this percentage of EWSR1 gene 
monosomy (mean of 17.2%) (p<0.001) 
(Figure 10). None of the studied SCNs 
disclosed EWSR1 rearrangements (with or 
without the FLI1 gene) or EWSR1 polysomy. 
Table 5 - Clinico-pathological features and results of the FISH analysis of SCN cases 
Case ID Gender Age 
EWSR1 polysomy  
(% cells) 
EWSR1 monosomy 
(% cells) 
EWSR1 
rearrangement 
A55 M 70 0 60 N 
A56 F 47 I I I 
A57 F 46 I I I 
A58 M 63 I I I 
A59 F 32 2 32 N 
A60 F 56 0 44 N 
A61 M 41 0 42 N 
A62 F 74 0 30 N 
A63 F 60 0 48 N 
A64 F NA 0 54 N 
   Legend: M, male; F, female; NA, Not available; N, Negative; I, Inconclusive   
Figure 10 - The FISH analysis demonstrates the 
presence of EWSR1 monosomy – one normal 
signal of EWSR1 (5’-orange and 3’-green), and 
two separated blue signals of FLI1 (A: 600x). 
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5 - DISCUSSION 
CEFTEs are exceptionally rare small cell tumours of the thyroid with apparently favorable 
prognosis but are difficult to distinguish from the usually aggressive PEEFTs, as they both 
have the EWSR1-FLI1 rearrangement. At variance with PEEFTs, CEFTE disclose a PTC 
component that shares with the small cell component of these tumours the EWSR1-FLI1 
rearrangement. Reported PEEFTs do not exhibit a PTC component even if the tumour 
develops in the thyroid (22). Besides the putative histogenetic link between CEFTE and 
PTCs, the SCNs were the alternative hypothesis for the origin of CEFTE, as previously 
described (5, 7). SCNs represent remnants of ultimobranchial body, are a normal 
component of the human thyroid gland and are positive for p63 (44, 52) as it happens in 
CEFTE (44, 53). In our series, none the studied SCNs disclosed the EWSR1 
rearrangement, a result that does not favour the hypothesis of CEFTEs having origin in 
SCNs; an assumption limited by the small number of samples that must be confirmed in a 
larger series of SCNs. 
The histogenetic relationship between SCN and PTC previously proposed (44) is also 
debatable at this point, considering that SCNs did not disclose EWSR1 polysomic nuclei 
and had a higher percentage of monosomic nuclei than PTC cases (0% vs 13.3% and 44.3 
vs 17.2%, respectively).  
The presence of the EWSR1-FLI1 rearrangement in the PTC component of all the studied 
CEFTEs of our series strongly suggests a histogenetic relation between CEFTE and PTC 
and reinforces the individualization of CEFTE as a single clinico-pathological entity. Taking 
into consideration that EWSR1 rearrangement occurs in 52% of PTC cases (without small 
cell component), the assumption that CEFTE may arise from a previously formed PTC that 
acquired the EWSR1-FLI1 fusion, becomes the more probable interpretation for CEFTE 
histogenesis.  
The EWSR1 rearrangement detected in non small cell associated-PTCs is not occurring, in 
most of the cases, with the FLI1 gene. Probably, when the fusion of the FLI1 with the 
EWSR1 occurs in a cell with other background genetic / epigenetic alterations there is loss 
of thyroid differentiation and acquisition of small cell phenotype, such as may happen in 
CEFTE. The two cases that disclosed EWSR1-FLI1 gene rearrangement, one follicular 
variant PTC and one classic PTC, did not present any particular clinico-pathological 
features to be individualized as indicating a special phenotype. The role of EWSR1-FLI1 
gene rearrangement in PTC neoplastic development should be studied in a larger series of 
positive cases with an extended follow-up to evaluate any association with prognosis and 
with transformation and subsequent overgrowth by CEFTE. Remains to be explained the 
mechanism by which the tumour cells lose their follicular differentiation, namely the 
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expression of TTF-1 and thyroglobulin, and acquire diffuse p63 expression. Poorly 
differentiated carcinoma and anaplastic carcinoma are examples of follicular derived 
tumours that may lose thyroglobulin expression, and anaplastic carcinoma may also 
disclose TTF-1 absence of expression. Nevertheless, both poorly differentiated and 
anaplastic carcinomas result from neoplastic progression of PTC in elderly patients and are 
associated to poor prognosis at variance with CEFTE that occurs in young patients and 
appears to have a favourable prognosis. The mechanism that underlays the acquisition of 
p63 expression can probably be similar to those mechanisms occurring in squamous 
metaplasia of follicular tumour cells, mucoepidermoid carcinoma, SETTLE (spindle cell 
tumour with thymus like elements) and CASTLE (carcinoma with thymus like elements) that 
also express p63. The abovementioned alterations in the differentiation of PTC follicular 
cells that appear to be related to progression into CEFTE should be distinct from those 
occurring in PEEFT of the thyroid that do not express p63 and cytokeratins as in CEFTE. 
PEEFT of the thyroid follow a clinical course similar to PEEFT in other locations and 
probably arise from neuroectodermal cells such as those that arise in soft tissues and bone.  
This is the first report of the presence of EWSR1 rearrangement in PTC. The results of our 
study indicate that EWSR1 rearrangement is present in about half of the cases, with a higher 
frequency in classic PTC than in PTC variants. Previous studies highlighting that BRAF 
mutation was the most frequent genetic alteration in classic PTC (32) are now debatable, 
as the EWSR1 rearrangement is detected in 90.0% of classic PTC of our series.  
PTC is a carcinoma rich in rearrangements such a RET-PTC, PAX8-PPARgama, NTRK1 
rearrangements, BRAF rearrangements and the new ALK rearrangements (56). The 
EWSR1 rearrangement is more frequent in PTC than rearrangements involving RET and 
NTRK1 genes, that also have a higher frequency in classic PTC than in PTC variants (42, 
48). The 26 PTC cases with EWSR1 rearrangement of our series, in which the fusion with 
the FLI1 gene was not observed, need to be further studied for the identification of the 
partner gene.   
In our series, CEFTE cases have had so far a favorable prognosis and none of the PTC 
cases disclosed distant metastases that may preclude a guarded prognosis. Taking this in 
consideration, we observed that the presence of EWSR1 rearrangement, polysomy or 
monosomy was not associated with clinico-pathological features indicative of clinical 
aggressiveness in PTCs. The high frequency of EWSR1 rearrangement in our series of 
PTC with low aggressiveness may indicate that this rearrangement is, in fact, not associated 
to prognosis as it happens with ALK rearrangement (57) and at variance with RET-PTC 
rearrangement that associates with an indolent “bonsai” phenotype that do not tend to 
evolve into poorly differentiated or anaplastic carcinoma (29). Nevertheless, the existence 
of a specific therapy for Ewing sarcomas (20) that harbor the EWSR1-FLI1 rearrangement 
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should be kept in the back of the mind as a possible therapy for patients with clinically 
aggressive PTC cases refractory to radioactive iodine treatment (45) that display the 
EWSR1-FLI1 rearrangement. 
Finally, there is a potential usefulness of the EWSR1 rearrangement in the diagnosis of 
PTC, particularly in the setting of fine needle aspiration biopsy (FNAB). Unfortunately, the 
rearrangement is particularly prevalent in classic PTCs which are the easiest to diagnose 
by FNAB.  
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6 - CONCLUSION AND FUTURE PERSPECTIVES  
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6.1 - CONCLUSION 
Summing up, we studied a series of PTC and SCN cases based in previous studies that 
defended that CEFTEs had origin in one of these entities. None of the SCNs studied by us 
were positive for the EWSR1 rearrangement with or without FLI1 fusion. In the PTC cases, 
52% of these cases were positive for the EWSR1 rearrangement and two cases were 
positive for the EWSR1-FLI1 rearrangement. This observation supports the origin of 
CEFTEs in PTCs. 
This is the first study where EWSR1-FLI1 rearrangement is described. This rearrangement 
occurs in a higher frequency in classic PTC than in other PTC variants.  
In our series, EWSR1 rearrangement was not associated with clinico-pathological features 
indicative of clinical aggressiveness in PTCs, which may indicate that this rearrangement is 
not associated to prognosis. 
The existence of a specific therapy for Ewing sarcomas with EWSR1-FLI1 rearrangement 
may be a possible therapy for patients with PTC that display EWSR1-FLI1 rearrangement 
and are refractory to radioactive iodine treatment. 
 
6.2 - FUTURE PERSPECTIVES 
Study the EWSR1 rearrangement in other thyroid tumours and benign lesions. 
Study the role of EWSR1 rearrangement in the cytological diagnosis of thyroid nodules. 
Study a larger series of PTC cases to evaluate associations between prognosis and 
presence of EWSR1 rearrangement.  
Study the 26 PTC cases of our series with EWSR1 rearrangement, where the fusion with 
the FLI1 gene was not observed, for the identification of the partner gene.  
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